ArticleRheumatology and therapy2018
Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database.
Article in Rheumatology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Spondyloarthritis Preceding and Following Inflammatory Bowel Disease Diagnosis and Risk Factors: A Temporal Trends Analysis in a Population-Based Cohort.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Race as a determinant of clinical characteristics, treatments, and outcomes of axial spondyloarthritis in the United States.Clinical rheumatology · 2026Review
- Diagnosing Ankylosing Spondylitis via Architecture-Modified ResNet and Combined Conventional Magnetic Resonance Imagery.Journal of imaging informatics in medicine · 2025Article
- Cost-Related Medication Behaviors for Patients With and Without Systemic Autoimmune Rheumatic Diseases.Arthritis care & research · 2025Article
- Association Between Diagnostic Delay and Economic and Clinical Burden in Axial Spondyloarthritis: A Multicentre Retrospective Observational Study.Rheumatology and therapy · 2025Article
- Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study.Rheumatology and therapy · 2024Article
- Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings).Current rheumatology reports · 2024Review
- Article
- Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2.Rheumatology and therapy · 2023Article
- Patients with Axial Spondyloarthritis are Great Consumers of Healthcare Resources, Especially Young and Women: Results from the Spanish Atlas.Rheumatology and therapy · 2023Article
- Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry.Arthritis & rheumatology (Hoboken, N.J.) · 2023Observational
- Associations of the circulating levels of cytokines with risk of ankylosing spondylitis: a Mendelian randomization study.Frontiers in immunology · 2023Article
- Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis.Journal of managed care & specialty pharmacy · 2022Article
- Does Gender Impact a Diagnosis of Ankylosing Spondylitis?ACR open rheumatology · 2022Article
- Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019.Orphanet journal of rare diseases · 2022Article
- Algorithm for the referral of patients with inflammatory back pain from primary care in Malaysia.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2021Review
- Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.Current rheumatology reports · 2021Review
- A novel IMU-based clinical assessment protocol for Axial Spondyloarthritis: a protocol validation study.PeerJ · 2021Article
- Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.Journal of managed care & specialty pharmacy · 2021Observational
- Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.Journal of managed care & specialty pharmacy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn addition to the considerable patient and societal burdens, the financial burdens of ankylosing spondylitis (AS) are substantial. Understanding both all-cause and AS-specific direct costs in patients with AS is important if we are to understand the financial impact on patients with AS and payers in the United States. This study assessed both all-cause and AS-specific healthcare utilization and direct costs in US patients with AS using administrative claims data.
methodsAdults aged ≥ 18 years enrolled in the MarketScan
resultsPatients with AS (N = 6679) had significantly higher rates of total all-cause inpatient admission (12% vs 6%), emergency department visits (23% vs 15%), nonhospital-based outpatient visits (100% vs 84%), hospital-based outpatient visits (68% vs 46%), other outpatient services (97% vs 81%), and medication use (97% vs 82%) compared with matched controls (N = 19,951). Patients with AS had approximately tenfold higher median total healthcare costs than matched controls ($24,978 vs $2139 per patient per year), largely driven by increased outpatient and pharmacy costs; P < 0.05 for all comparisons. The median (IQR) total AS-specific healthcare costs were $10,250 ($774, $28,824).
conclusionIn this analysis of claims data, increased outpatient and pharmacy costs were key contributors to higher all-cause total healthcare costs in US patients with AS.
fundingNovartis Pharmaceuticals Corporation, East Hanover, NJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.